NTLA
Intellia Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.74
+0.47%Sep 4, 2026, 12:50 UTC
Intellia Therapeutics entered into a non-dilutive debt facility with OrbiMed for up to $400 million, with $75 million funded upfront and an additional $325 million available upon achieving milestones.
Source:Aug 7, 2026, 06:05 UTC
Intellia Therapeutics resumed enrollment in Phase III studies of its gene-editing therapy nex-z for transthyretin amyloidosis during Q2 2026.
Source:Aug 7, 2026, 06:05 UTC
Intellia Therapeutics announced positive Phase III results for its gene-editing therapy lonvo-z in hereditary angioedema during Q2 2026.
Source:Aug 6, 2026, 13:21 UTC
Intellia Therapeutics reported a Q2 2026 loss of $0.8 per share, in line with the Zacks Consensus Estimate, compared to a loss of $0.99 per share a year ago.
Jun 15, 2026, 13:39 UTC
Intellia Therapeutics reported additional positive findings from its global Phase 3 HAELO trial evaluating lonvo-z, its investigational CRISPR-based treatment for hereditary angioedema.
Source: